Expression of APRIL in diffuse large B cell lymphomas from patients with systemic lupus erythematosus and rheumatoid arthritis

Journal of Rheumatology

Volumn 38, Issue 9, 2011, Pages 1891-1897

  Löfström, Björn ^a,e   Backlin, Carin ^b   Pettersson, Tom ^d   Lundberg, Ingrid E ^a   Baecklund, Eva ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e Mälar Hospital Eskilstuna   (Sweden)

Author keywords

A proliferating inducing ligand; APRIL; Diffuse large B cell lymphoma; Epstein Barr virus; Malignant lymphoma; Rheumatoid arthritis; Systemic lupus erythematosus

Indexed keywords

APRIL PROTEIN; CYTOTOXIC AGENT; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; PROTEIN ANTIBODY;

ADULT; AGED; ANN ARBOR STAGE; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CHRONIC INFLAMMATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; LYMPHOCYTOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; TUMOR BIOPSY;

ADULT; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; LIGANDS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; RISK FACTORS; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 80052336465     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.101190     Document Type: Article

References (37)

1. Isomäki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukaemia and myeloma in patients with rheumatoid arthritis. J Chron Dis 1978;31:691-6.
2. Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307-11. (Pubitemid 23068804)
3. Mellemkjaer L, Andersen V, Linet MS, Gridley G, Hoover R, Olsen JH. Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:761-8. (Pubitemid 27157584)
4. Bernatsky S, Boivin JF, Joseph L, Rajan R, Zoma A, Manzi S, et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 2005;52:1481-90. (Pubitemid 40663940)
5. Smedby KE, Askling J, Mariette X, Baecklund E. Autoimmune and inflammatory disorders and risk of malignant lymphomas - an update. J Intern Med 2008;264:514-27.
6. Pettersson T, Pukkala E, Teppo L, Friman C. Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis 1992;51:437-9.
7. Baecklund E, Sundström C, Ekbom A, Catrina AI, Biberfeld P, Feltelius N, et al. Lymphoma subtypes in patients with rheumatoid arthritis. Increased proportion of diffuse large B cell lymphoma. Arthritis Rheum 2003;48:1543-50. (Pubitemid 36682361)
8. Löfström B, Backlin C, Sundström C, Ekbom A, Lundberg IE. A closer look at non-Hodgkin's lymphoma in a national Swedish systemic lupus erythematosus cohort - a nested case-control study. Ann Rheum Dis 2007;66:1627-32. (Pubitemid 350205452)
9. Baecklund E, Ekbom A, Sparén P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. Br Med J 1998;317:180-1. (Pubitemid 28325543)
10. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Chronic inflammation, not its treatment, increases lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701.
11. King JK, Costenbader KH. Characteristics of patients with systemic lupus erythematosus and non-Hodgkin's lymphoma. Clin Rheumatol 2007;26:1491-4. (Pubitemid 47193566)
12. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001;44:1313-9. (Pubitemid 32537529)
13. Zhang J, Roschke V, Baker KP, Wang Z, Alarcon CS, Fessler BJ, et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001;166:6-10. (Pubitemid 32038409)
14. Koyama T, Tsukamoto H, Miyagi Y, Himeji D, Otsuka J, Miyagawa H, et al. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis 2005;64:1065-7. (Pubitemid 40909524)
15. Tan SM, Xu D, Roschke V, Perry JW, Arkfeld DG, Ehresmann GR, et al. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 2003;48:982-92. (Pubitemid 36418240)
16. Gabay C, Krenn V, Bosshard C, Seemayer CA, Chizzolini C, Huard B. Synovial tissues concentrate secreted APRIL. Arthritis Res Ther 2009;11:R144.
17. Hahne M, Kataoka T, Schröter M, Hofmann K, Irmler M Bodmer JL, et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 1998;188:1185-90. (Pubitemid 28443341)
18. Schwaller J, Schneider P, Mhawech-Fauceglia P, McKee T, Myit S, Matthes T, et al. Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlated with human B-cell lymphoma aggressiveness. Blood 2007;109:331-8. (Pubitemid 46053074)
19. World Health Organization. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissue. Geneva: IARC Press; 2001.
20. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
21. Björnådal L, Löfström B, Yin L, Lundberg I, Ekbom A. Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol 2000;31:66-71.
22. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
23. Berglund M, Thunberg U, Amini RM, Book M, Roos G, Erlanson M, et al. Evaluation of immunophenotype in diffuse large B-cell lymphoma and impact on prognosis. Mod Pathol 2005;18:1113-20. (Pubitemid 41224503)
24. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;03:275-82. (Pubitemid 38029949)
25. Chang KL, Chen YY, Shibata D, Weiss LM. Description of an in situ hybridization methodology for detection of Epstein-Barr virus RNA in paraffin-embedded tissues, with a survey of normal and neoplastic tissues. Diagn Mol Pathol 1992;1:246-55.
26. Morel J, Roubille C, Planelles L, Rocha C, Fernandez L, Lukas C, et al. Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus. Ann Rheum Dis 2009;68:997-1002.
27. George-Chandy A, Trysberg E, Eriksson K. Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms. Arthritis Res Ther 2008;10:R97.
28. Roosnek E, Burjanadze M, Dietrich PY, Matthes T, Passweg J, Huard B. Tumors that look for their springtime in APRIL. Crit Rev Oncol Hematol 2009;72:91-7.
29. He B, Chadburn A, Jou E, Schattner EJ, Knowles DM, Cerutti A. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol 2004;172:3268-79. (Pubitemid 38263719)
30. Ansell SM, Witzig TE, Inwards DJ, Porrata LF, Ythier A, Ferrande L, et al. Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma. Clin Cancer Res 2008;14:1105-10. (Pubitemid 351302557)
31. Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007;56:4142-50. (Pubitemid 350262342)
32. Tak PP, Thurlings RM, Rossier C, Nestorov I, Dimic A, Mircetic V, et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum 2008;58:61-72.
33. Bracewell C, Isaacs JD, Emery P, Ng WF. Atacicept, a novel B-cell-targeting biological therapy for the treatment of rheumatoid arthritis. Exp Opin Biol Ther 2009;9:909-19.
34. Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol/Hematol 2005;56:155-67. (Pubitemid 41278654)
35. He B, Raab-Traub N, Casali P, Cerutti A. EBV-encoded latent membrane protein 1 cooperates with BAFF/BLyS and APRIL to induce T cell-independent Ig heavy chain class switching. J Immunol 2003;171:5215-24. (Pubitemid 37432806)
36. Kamel OW, van de Rijn M, Hanasono MM, Warnke RA. Immunosuppression- associated lymphoproliferative disorders in rheumatic patients. Leuk Lymphoma 1995;16:363-8.
37. Kamel OW, Holly EA, van de Rijn M, Lele C, Sah A. A population based, case control study of non-Hodgkin's lymphoma in patients with rheumatoid arthritis. J Rheumatol 1999;26:1676-80. (Pubitemid 29367304)